HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ StudyIvonne Haffner, Florian Lordick, Albrecht Kretzschmar et al.|Journal of Clinical Oncology|2021Cited by 124
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study GroupRalf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Kirsten Merx et al.|Journal of Clinical Oncology|2022Cited by 97
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Georg Martin Haag et al.|Journal of Clinical Oncology|2020Cited by 91
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective <scp>QOLIXANE</scp> trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registrySalah‐Eddin Al‐Batran, Ursula Vehling‐Kaiser, Ralf‐Dieter Hofheinz et al.|International Journal of Cancer|2020Cited by 21
Abstract 2615: Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ studyFlorian Lordick, Christian Wittekind, Ivonne Haffner et al.|Cancer Research|2018Cited by 5